Supreme Court Scrutinizes Clinical Trial Rules: Balancing Public Health and Corporate Interests
GS2GS4
The Supreme Court has ordered a comprehensive review of the 'New Drugs and Clinical Trials (Amendment) Rules, 2024' to prevent the exploitation of human subjects. The court emphasized that clinical research in India must prioritize domestic health needs over the commercial interests of multinational pharmaceutical companies.
The Supreme Court of India has recently initiated a rigorous scrutiny of the 'New Drugs and Clinical Trials (Amendment) Rules, 2024.' This judicial intervention stems from concerns regarding the adequacy of existing safeguards for human subjects participating in clinical trials. The apex court’s directive for a comprehensive review highlights a critical tension between the rapid expansion of the pharmaceutical industry and the ethical obligation to protect vulnerable citizens from exploitation.
At the heart of the matter is the court's observation that clinical trials conducted within the country must primarily serve the health interests of the domestic population. The bench emphasized that India should not merely serve as a testing ground for multinational pharmaceutical companies seeking to further their commercial interests without providing tangible health benefits to the local community. This underscores the principle of 'health sovereignty,' where regulatory frameworks must ensure that the drugs being tested address the specific disease burden and epidemiological profile of the Indian people.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.